Efficacy

• In ESPRIT, the overall risk ratio for DP + ASA vs. ASA was 0.82
  (95% CI 0.74–0.91).
• The number needed to treat (NNT)/year was 104 (55–1,006).
• The overall results showed a 20% relative risk reduction in the comparison of dipyridamole and ASA (also marketed as Aggrenox®/Asasantin®) with ASA alone for the composite endpoint, death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication.

Time-to-Event Curves for Primary Outcome Event and all Ischaemic Events